Tag: 100-200

On March 31, 2017, Ostakhov, S. S.; Sultanbaev, M. V.; Ovchinnikov, M. Yu.; Kayumov, R. R.; Khursan, S. L. published an article.COA of Formula: C5H6N2O2 The title of the article was Spectral-luminescence and quantum-chemical study of the anionic forms of 5-fluorouracil. And the article contained the following:

A spectral-luminescence study of neutral (pH 7) and alk. (pH 11 and 14) aqueous solutions of the anticancer drugs 5-fluorouracil (FU) and tegafur has been performed. The fluorescence spectra of the N3- and N1-centered anions of 5-fluorouracil, its dianion, and the tegafur monoanion with emission maxima at wavelengths (λem) of 358, 372, 366, and 358 nm and photoluminescence quantum yields (φ) of 11.2 x 10-4, 35.1 x 10-4, 26.5 x 10-4, and 8.6 x 10-4, resp., have been recorded for the first time. The fluorescence characteristics of the FU anionic forms have been related to the magnetic shielding constant as one of the criteria of aromaticity. The experimental process involved the reaction of 6-Methylpyrimidine-2,4(1H,3H)-dione(cas: 626-48-2).COA of Formula: C5H6N2O2

The Article related to fluorouracil tegafur uv fluorescence spectra ph effect, Physical Organic Chemistry: Absorption, Emission, Reflection, and Scattering Spectra (Ultraviolet and Visible, Infrared and Fourier Transform Infrared, Raman, Microwave, Photoelectron, Fluorescence, Phosphorescence, etc.) and other aspects.COA of Formula: C5H6N2O2

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On September 12, 2003, Cadilla, Rodolfo; Henke, Brad Richard; Lambert, Millard H., III; Liu, Guangcheng Kevin; Smith, Jennifer Susan published a patent.Safety of 2-Chloro-5-isopropylpyrimidine The title of the patent was Preparation of phenoxyalkanoic acid derivatives as hPPAR activators for treatment of diabetes and cardiovascular diseases. And the patent contained the following:

Title compounds I [wherein R1 and R2 = independently H, F, CF3, or alkyl; or CR1R2 = cycloalkyl; R3 = (un)substituted heteroaryl; R4 and R5 = independently H, (perfluoro)alkyl, (perfluoro)alkoxy, halo, or CN; R6 = (un)substituted Ph or heteroaryl; R7 and R8 = independently H, F, CF3, or alkyl with the proviso that the C to which R7 and R8 are bonded is either meta or para to the depicted O; m and n = independently 1-2; or pharmaceutically acceptable salts, solvates, acid isosteres, or hydrolyzable esters thereof] were prepared as human peroxisome proliferator activated receptor (hPPAR) activators (no data). For example, Me 2-[4-[2-[[2,4-bis(trifluoromethyl)benzyl]amino]ethyl]phenoxy]-2-methylpropanoate was coupled with 2-chloro-5-ethylpyrimidine using DIEA in toluene to give the tertiary amine (38%). Hydrolysis of the ester with NaOH provided II (48%). Methods for treating diseases or conditions associated with hPPARα, hPPARγ, or hPPARδ, such as diabetes and cardiovascular diseases, comprising administration of a therapeutically effective amount of I or a pharmaceutical composition comprising I are also disclosed (no data). The experimental process involved the reaction of 2-Chloro-5-isopropylpyrimidine(cas: 596114-50-0).Safety of 2-Chloro-5-isopropylpyrimidine

The Article related to phenoxyalkanoic acid preparation ppar activator antidiabetic cardiovascular agent, Benzene, Its Derivatives, and Condensed Benzenoid Compounds: Carboxylic Acids and Peroxycarboxylic Acids and Their Sulfur-Containing Analogs and Salts and other aspects.Safety of 2-Chloro-5-isopropylpyrimidine

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On June 28, 2019, Portalone, Gustavo published an article.Application of 626-48-2 The title of the article was 6-Methyluracil: a redetermination of polymorph (II). And the article contained the following:

6-Methyluracil, C5H6N2O2, exists in two crystalline phases: form (I), monoclinic, space group P21/c [Reck et al. (1988). Acta Crystalline A44, 417-421] and form (II), monoclinic, space group C2/c [Leonidov et al. (1993). Russ. J. Phys. Chem.67, 2220-2223]. The structure of polymorph (II) has been redetermined providing a significant increase in the precision of the derived geometric parameters. In the crystal, mols. form ribbons approx. running parallel to the c-axis direction through N-H···O hydrogen bonds. The radical differences observed between the crystal packing of the two polymorphs may be responsible in form (II) for an increase in the contribution of the polar canonical forms C-(O-)=N-H+ relative to the neutral canonical form C(=O)-N-H induced by hydrogen-bonding interactions. The experimental process involved the reaction of 6-Methylpyrimidine-2,4(1H,3H)-dione(cas: 626-48-2).Application of 626-48-2

The Article related to methyluracil polymorph redetn hydrogen bond crystal structure, Crystallography and Liquid Crystals: Crystallization and Recrystallization, Nucleation, Crystal Growth, Epitaxy, Nonepitaxial Film Deposition and other aspects.Application of 626-48-2

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On August 17, 2006, Beard, Charles D.; Lee, Ving J.; Whittle, C. Ed published a patent.Related Products of 89792-07-4 The title of the patent was Process for the preparation of aza-annelated pyrroles, thiophenes and furans as potential bioisosteres of indole, benzofuran and benzothiophene scaffolds. And the patent contained the following:

A process for the preparation of aza-annelated pyrroles, thiophenes and furans I [wherein T = (un)substituted NH, O or S; R2 = H, (halo)alkyl, (un)substituted aryl, etc.; W, X, Y, Z = (un)substituted CH or N with limitations; D = H or Br], which are potentially useful as bioisosteres of indole, benzofuran and benzothiophene scaffolds, is disclosed. The process comprises coupling iodides II with acetylene compounds CHCCH2R2 or silyl group-protected acetylene such as CHC-TMS, and cyclizing the resultant alkynes in protic solvents. Key features of the method include regioselective substitution in the iodine sites and tolerance of a wide range of sensitive functional groups. For instance, regioselective Sonogashira reaction of 5-bromo-3-iodo-2-pyridinamine (preparation given) with CHC-TMS in toluene in the presence of PdCl2(PPh3)2, CuI and Et3N gave ethynylpyridinamine III in 80% yield. This compound underwent t-BuOK-mediated intramol. cyclization in refluxing t-butanol to afford 5-bromo-1H-pyrrolo[2,3-b]pyridine in 60% yield. The experimental process involved the reaction of 2-Methyl-7H-pyrrolo[2,3-d]pyrimidine(cas: 89792-07-4).Related Products of 89792-07-4

The Article related to iodopyridinamine preparation acetylene palladium copper sonogashira coupling, ethynylpyridinamine preparation intramol cyclization, pyrrolopyridine azaindole preparation, Heterocyclic Compounds (More Than One Hetero Atom): Fused-Ring Systems With Two Or More Hetero Atoms, No More Than One Hetero Atom Per Ring and other aspects.Related Products of 89792-07-4

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On September 15, 2022, Arns, Stephen Paul; Hsieh, Tom Han Hsiao; Shidmoossavee, Fahimeh S.; Tan, Jason Samuel; Yee, Leanna; Paquette, Jay John; Jaquith, James Brian; Osborne, Simon; Smiljanic-Hurley, Ela; Hamby, Callum; Smyth, Elliott; Ambler, Martin; Minchinton, Andrew I.; Kyle, Alastair H.; Baker, Jennifer H. E. published a patent.Recommanded Product: 596114-50-0 The title of the patent was Preparation of 7-morpholino-1,6-naphthyridin-5-yl derivatives and use thereof as DNA-PK inhibitors. And the patent contained the following:

The present disclosure provides compounds of formula I and methods for inhibiting DNA-dependent protein kinase (DNA-PK). Aspects of the present disclosure also include methods of using the compounds to treat diseases, including, but not limited to, cancer. Compounds of formula I wherein R1a is H and C1-6 alkyl; R1b is C1-6 alkyl, C3-8 cycloalkyl, 3-8 heterocycloalkyl, etc.; R2 is halo, cyano, C1-6 alkyl, etc.; R3 is H, halo, C1-6 alkyl and C1-6 haloalkyl; R4 is C1-6 alkyl and C1-6 haloalkyl; and their pharmaceutically acceptable salts, are claimed. Example compound II was prepared by a multistep procedure (procedure given). The invention compounds were evaluated for their DNA-PK inhibitory activity (data given). The experimental process involved the reaction of 2-Chloro-5-isopropylpyrimidine(cas: 596114-50-0).Recommanded Product: 596114-50-0

The Article related to morpholino naphthyridinyl preparation dna protein kinase inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Fused-Ring Systems With Two Or More Hetero Atoms, No More Than One Hetero Atom Per Ring and other aspects.Recommanded Product: 596114-50-0

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On March 18, 2021, Minchinton, Andrew Ivor; Kyle, Alastair Hugh; Evans, James; Mann, Samuel Edward; Hynd, George published a patent.SDS of cas: 944129-00-4 The title of the patent was 1,6-Naphthridine derivatives as DNA-PK inhibiting compounds and prodrugs. And the patent contained the following:

The present disclosure relates to DNA-PK inhibiting compounds of formula I and prodrugs thereof that are useful in the treatment of diseases, including cancer, by sensitizing cancers to therapies such as chemotherapy and radiotherapy and the preparation of such compounds Compound I, wherein Y is O and NR5; each R1 is independently C1-6 alkyl and C1-6 haloalkyl; R2 is H, C1-6 alkyl, C1-6 haloalkyl, etc.; each R3 is independently halo, cyano, C1-6 alkyl, R4 is L1L2R9a, etc.; R5 is independently H, C1-6 alkyl, etc.; L1 is independently absent and (un)substituted C1-6 alkylene; L2 is absent and L3L4; L3 is (un)substituted C1-6 alkylene, (un)substituted C3-6 cycloalkyl, (un)substituted 3- to 11-membered heterocycloalkyl, etc.; L4 is absent, NR13a and O; R9a are Ph, naphthyl, 3- to 8-membered heterocycloalkyl, etc.; R13a is H and C1-6 alkyl; n is 0, 1, 2 and 3; m is 0, 1, 2, 3 and 4; and prodrug, pharmaceutically acceptable salts and N-oxide of compound I and prodrug thereof, are claimed. Compound II was prepared using a multistep procedure (procedure given). Compound II was evaluated for DNA-PK inhibition yielding an IC50 of 82 nM using ADP-Glo and 832 nM using MSD FaDu. The experimental process involved the reaction of Methyl 6-amino-2-chloropyrimidine-4-carboxylate(cas: 944129-00-4).SDS of cas: 944129-00-4

The Article related to naphthridine preparation dna pk inhibition cancer, Heterocyclic Compounds (More Than One Hetero Atom): Fused-Ring Systems With Two Or More Hetero Atoms, No More Than One Hetero Atom Per Ring and other aspects.SDS of cas: 944129-00-4

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On April 8, 2021, Folmer, Rutger; Hekking, Koen F. W.; Calpe, Blaise; Mueller, Gerhard; Fabritius, Charles-Henry published a patent.HPLC of Formula: 89792-07-4 The title of the patent was Azaindole derivatives and related compounds as inhibitors of dual specificity tyrosine phosphorylation regulated kinase 1B and their preparation. And the patent contained the following:

The invention relates to compounds of formula I, optionally in the form of a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, in particular for use in the treatment, amelioration or prevention of cancer, Alzheimer, Parkinson, Down syndrome, metabolic syndrome, diabetes and/or osteoarthritis. Compounds of formula I wherein X1 is N, CH and CF; X2 = N, CH and CR1; each R2 is independently H and R1; Y1 is S and O; Y2 is C, CN, CMe, CCl and CF; Y3 is N, CH and CR1; A is (un)substituted (mono/bi/tri)cyclic heterocyclyl; R1 is (un)substituted C1-6 alkyl, halo, CN, NO2, etc.; and pharmaceutically acceptable salts, solvates, cocrystals, tautomers, racemates, enantiomers, diastereomers and mixtures thereof, are claimed. Example compound II was prepared by cyclization of 2-chloro-1-(1H-pyrrolo[2,3-b]pyridin-3-yl)ethan-1-one with 1H-imidazole-4-carbothioamide. The invention compounds were evaluated for their DYRK1B inhibitory activity. From the assay it was determined that compound II exhibited IC50 value in the range of 10 nM to < 100 nM. The experimental process involved the reaction of 2-Methyl-7H-pyrrolo[2,3-d]pyrimidine(cas: 89792-07-4).HPLC of Formula: 89792-07-4

The Article related to azaindole preparation dyrk1b inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Fused-Ring Systems With Two Or More Hetero Atoms, No More Than One Hetero Atom Per Ring and other aspects.HPLC of Formula: 89792-07-4

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Wolf, Thomas J. A.; Paul, Alexander C.; Folkestad, Sarai D.; Myhre, Rolf H.; Cryan, James P.; Berrah, Nora; Bucksbaum, Phil H.; Coriani, Sonia; Coslovich, Giacomo; Feifel, Raimund; Martinez, Todd J.; Moeller, Stefan P.; Mucke, Melanie; Obaid, Razib; Plekan, Oksana; Squibb, Richard J.; Koch, Henrik; Guhr, Markus published an article in 2021, the title of the article was Transient resonant Auger-Meitner spectra of photoexcited thymine.Recommanded Product: 65-71-4 And the article contains the following content:

We present the first investigation of excited state dynamics by resonant Auger-Meitner spectroscopy (also known as resonant Auger spectroscopy) using the nucleobase thymine as an example. Thymine is photoexcited in the UV and probed with X-ray photon energies at and below the oxygen K-edge. After initial photoexcitation to a ππ* excited state, thymine is known to undergo internal conversion to an nπ* excited state with a strong resonance at the oxygen K-edge, red-shifted from the ground state π* resonances of thymine (see our previous study Wolf, et al., Nat. Commun., 2017, 8, 29). We resolve and compare the Auger-Meitner electron spectra associated both with the excited state and ground state resonances, and distinguish participator and spectator decay contributions. Furthermore, we observe simultaneously with the decay of the nπ* state signatures the appearance of addnl. resonant Auger-Meitner contributions at photon energies between the nπ* state and the ground state resonances. We assign these contributions to population transfer from the nπ* state to a ππ* triplet state via intersystem crossing on the picosecond timescale based on simulations of the X-ray absorption spectra in the vibrationally hot triplet state. Moreover, we identify signatures from the initially excited ππ* singlet state which we have not observed in our previous study. The experimental process involved the reaction of 5-Methylpyrimidine-2,4(1H,3H)-dione(cas: 65-71-4).Recommanded Product: 65-71-4

The Article related to thymine photoexcitation auger photoelectron spectra, Physical Organic Chemistry: Resonance Spectra (Electron Spin, Nuclear Magnetic and Fourier Transform Nuclear Magnetic, Quadrupole, etc.) and other aspects.Recommanded Product: 65-71-4

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On November 1, 2012, Holson, Edward; Wagner, Florence Fevrier; Weiwer, Michel published a patent.Reference of 6,7-Dihydro-5H-pyrrolo[3,4-d]pyrimidine hydrochloride The title of the patent was Preparation of heterocyclic phenyl carboxamide compounds as inhibitors of histone deacetylase for therapy. And the patent contained the following:

The present invention relates to compounds of formula I, or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein U is (un)substituted CH2-CH2, (un)substituted NH, (un)substituted NH-NH-, and O; J is NH2, OH, and SH; V is C and N, with provisos; X is H, deuterium, Me, CF3, and halo; R2a, R2b, and R2c are independently H, halo, OH, NH2, and C1-8 alkyl; R5 is H, deuterium, halo, OH, C1-8 alkyloxy, etc.; and t = 0-3. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. These compounds are useful for promoting cognitive function and enhancing learning and memory formation. In addition, these compounds are useful for treating, alleviating, and/or preventing various conditions, including for example, neurol. disorders, memory and cognitive function disorders/impairments, extinction learning disorders, fungal diseases and infections, inflammatory diseases, hematol. diseases, and neoplastic diseases in humans and animals. Synthetic procedures for preparing I are exemplified. Example compound II was prepared in a multistep synthetic scheme that involved reaction of tetrahydro-2H-pyran-4-carboxylic acid with tert-Bu [2-amino-4-(thiophen-2-yl)phenyl]carbamate and deprotection of the intermediate formed to give II. II had IC50 values between 1.1 and 5 μM in assays measuring HDAC1 and HDAC3 inhibition and between .11 and 1 μM in an HDA2 inhibition assay following a trypsin-coupled protocol. The experimental process involved the reaction of 6,7-Dihydro-5H-pyrrolo[3,4-d]pyrimidine hydrochloride(cas: 1187830-46-1).Reference of 6,7-Dihydro-5H-pyrrolo[3,4-d]pyrimidine hydrochloride

The Article related to preparation heterocyclic ph carboxamide compound inhibitor histone deacetylase therapy, Benzene, Its Derivatives, and Condensed Benzenoid Compounds: Amides, Amidines, Imidic Esters, Hydrazides, and Hydrazonic Esters and other aspects.Reference of 6,7-Dihydro-5H-pyrrolo[3,4-d]pyrimidine hydrochloride

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Hua, XinZhong; Hua, LinQiang; Liu, XiaoJun published an article in 2016, the title of the article was The methyl- and aza-substituent effects on nonradiative decay mechanisms of uracil in water: a transient absorption study in the UV region.Related Products of 626-48-2 And the article contains the following content:

The nonradiative decay dynamics of photo-excited uracil (Ura) and its derivatives, i.e., thymine (5-methyluracil, Thy), 6-methyluracil (6-MU) and 6-azauracil (6-AU) in water, has been studied using a femtosecond transient absorption method. The mols. are populated in the lowest 1ππ* state by a pump pulse at 266 nm, and a broadband continuum in the deep UV region is then employed as the probe. The extension of the continuous UV probe down to 250 nm enables us to investigate comprehensively the population dynamics of the ground states for those mols. and to uncover the substituent effects on nonradiative decay dynamics of uracil. Vibrational cooling in the ground states of Ura, Thy and 6-MU has been directly observed for the first time, providing solid evidence of the ultrafast 1ππ* → S0 decay. In combination with the ground state bleaching signals, it is consolidated that their lowest 1ππ* state decays via two parallel pathways, i.e., 1ππ* → S0 and 1ππ* → 1nπ*. Moreover, the contribution of the 1ππ* → 1nπ* channel is found to be much smaller for Thy or 6-MU than for Ura. Different from methyl-substitution, the initial 1ππ* state of the aza-substituent 6-AU decays primarily to the 1nπ* state, while the 1ππ* → S0 channel can be negligible. The experimental process involved the reaction of 6-Methylpyrimidine-2,4(1H,3H)-dione(cas: 626-48-2).Related Products of 626-48-2

The Article related to methyluracilsubstituent effect transient nonradiative transition, Radiation Chemistry, Photochemistry, and Photographic and Other Reprographic Processes: Radiation Chemistry and Photochemistry and other aspects.Related Products of 626-48-2

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia